(ZEG) AstraZeneca - Overview
Oncology, Cardiovascular, Respiratory, Immunology, Rare-Disease
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 2.08% |
| Yield on Cost 5y | 4.35% |
| Yield CAGR 5y | 4.89% |
| Payout Consistency | 96.9% |
| Payout Ratio | 51.7% |
| Risk 5d forecast | |
|---|---|
| Volatility | 27.5% |
| Relative Tail Risk | -9.18% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.58 |
| Alpha | 15.83 |
| Character TTM | |
|---|---|
| Beta | -0.102 |
| Beta Downside | 0.243 |
| Drawdowns 3y | |
|---|---|
| Max DD | 28.22% |
| CAGR/Max DD | 0.30 |
Description: ZEG AstraZeneca January 26, 2026
AstraZeneca PLC (XETRA:ZEG) is a global biopharmaceutical firm that discovers, develops, manufactures and commercialises prescription medicines across oncology, cardiovascular-renal-metabolism, respiratory-immunology, vaccines and rare diseases, serving primary and specialty-care physicians in the U.K., U.S., Europe and Asia.
Its flagship portfolio includes oncology agents such as Tagrisso, Imfinzi, Lynparza and Enhertu; metabolic drugs like Farxiga and Brilinta; respiratory products such as Symbicort and Fasenra; and biologics for rare diseases including Soliris and Ultomiris. Recent pipeline highlights include FDA approval of Enhertu for HER2-positive breast cancer (Q2 2024) and a positive Phase III read-out for the Tagrisso-plus-chemo regimen in metastatic non-small-cell lung cancer.
In FY 2023 AstraZeneca reported €44.6 bn in total revenue, with oncology sales up 12 % YoY to €13.5 bn, and R&D spending at €7.0 bn (≈16 % of sales). The company is leveraging AI and quantum-computing partnerships-most notably a strategic agreement with Tempus to build the largest multimodal oncology foundation model and a collaboration with IonQ to accelerate computational chemistry.
Key sector drivers remain an aging global population, rising prevalence of chronic diseases, and accelerating adoption of digital-health and AI-enabled drug discovery, which together underpin a projected 7 % CAGR for the global pharma market through 2028.
For a deeper quantitative assessment, consult the ValueRay analyst toolkit.
Piotroski VR‑10 (Strict, 0-10) 8.5
| Net Income: 9.40b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.09 > 0.02 and ΔFCF/TA 2.83 > 1.0 |
| NWC/Revenue: -7.08% < 20% (prev -3.46%; Δ -3.62% < -1%) |
| CFO/TA 0.13 > 3% & CFO 15.14b > Net Income 9.40b |
| Net Debt (24.52b) to EBITDA (17.98b): 1.36 < 3 |
| Current Ratio: 0.88 > 1.5 & < 3 |
| Outstanding Shares: last quarter (1.56b) vs 12m ago -0.06% < -2% |
| Gross Margin: 82.28% > 18% (prev 0.81%; Δ 8147 % > 0.5%) |
| Asset Turnover: 52.99% > 50% (prev 48.80%; Δ 4.19% > 0%) |
| Interest Coverage Ratio: 8.27 > 6 (EBITDA TTM 17.98b / Interest Expense TTM 1.57b) |
Altman Z'' 0.95
| A: -0.04 (Total Current Assets 29.94b - Total Current Liabilities 34.05b) / Total Assets 114.46b |
| B: 0.07 (Retained Earnings 8.21b / Total Assets 114.46b) |
| C: 0.12 (EBIT TTM 12.95b / Avg Total Assets 109.69b) |
| D: 0.16 (Book Value of Equity 10.64b / Total Liabilities 68.48b) |
| Altman-Z'' Score: 0.95 = BB |
Beneish M -2.98
| DSRI: 1.06 (Receivables 14.34b/11.88b, Revenue 58.13b/51.21b) |
| GMI: 0.98 (GM 82.28% / 80.88%) |
| AQI: 0.94 (AQ_t 0.62 / AQ_t-1 0.66) |
| SGI: 1.14 (Revenue 58.13b / 51.21b) |
| TATA: -0.05 (NI 9.40b - CFO 15.14b) / TA 114.46b) |
| Beneish M-Score: -2.98 (Cap -4..+1) = A |
What is the price of ZEG shares?
Over the past week, the price has changed by +2.16%, over one month by -0.86%, over three months by +10.46% and over the past year by +19.50%.
Is ZEG a buy, sell or hold?
What are the forecasts/targets for the ZEG price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 149.4 | -4.4% |
ZEG Fundamental Data Overview January 26, 2026
Market Cap USD = 291.54b (243.39b EUR * 1.1978 EUR.USD)
P/E Trailing = 30.6641
P/E Forward = 17.9211
P/S = 4.1873
P/B = 6.2342
P/EG = 1.0601
Revenue TTM = 58.13b USD
EBIT TTM = 12.95b USD
EBITDA TTM = 17.98b USD
Long Term Debt = 24.70b USD (from longTermDebt, last quarter)
Short Term Debt = 6.58b USD (from shortTermDebt, last quarter)
Debt = 32.66b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 24.52b USD (from netDebt column, last quarter)
Enterprise Value = 316.02b USD (291.54b + Debt 32.66b - CCE 8.18b)
Interest Coverage Ratio = 8.27 (Ebit TTM 12.95b / Interest Expense TTM 1.57b)
EV/FCF = 29.79x (Enterprise Value 316.02b / FCF TTM 10.61b)
FCF Yield = 3.36% (FCF TTM 10.61b / Enterprise Value 316.02b)
FCF Margin = 18.25% (FCF TTM 10.61b / Revenue TTM 58.13b)
Net Margin = 16.17% (Net Income TTM 9.40b / Revenue TTM 58.13b)
Gross Margin = 82.28% ((Revenue TTM 58.13b - Cost of Revenue TTM 10.30b) / Revenue TTM)
Gross Margin QoQ = 81.16% (prev 82.89%)
Tobins Q-Ratio = 2.76 (Enterprise Value 316.02b / Total Assets 114.46b)
Interest Expense / Debt = 1.07% (Interest Expense 349.0m / Debt 32.66b)
Taxrate = 21.86% (709.0m / 3.24b)
NOPAT = 10.12b (EBIT 12.95b * (1 - 21.86%))
Current Ratio = 0.88 (Total Current Assets 29.94b / Total Current Liabilities 34.05b)
Debt / Equity = 0.71 (Debt 32.66b / totalStockholderEquity, last quarter 45.89b)
Debt / EBITDA = 1.36 (Net Debt 24.52b / EBITDA 17.98b)
Debt / FCF = 2.31 (Net Debt 24.52b / FCF TTM 10.61b)
Total Stockholder Equity = 43.11b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.57% (Net Income 9.40b / Total Assets 114.46b)
RoE = 21.80% (Net Income TTM 9.40b / Total Stockholder Equity 43.11b)
RoCE = 19.09% (EBIT 12.95b / Capital Employed (Equity 43.11b + L.T.Debt 24.70b))
RoIC = 13.81% (NOPAT 10.12b / Invested Capital 73.23b)
WACC = 5.07% (E(291.54b)/V(324.20b) * Re(5.54%) + D(32.66b)/V(324.20b) * Rd(1.07%) * (1-Tc(0.22)))
Discount Rate = 5.54% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 0.0 | Cagr: 0.0%
[DCF Debug] Terminal Value 87.49% ; FCFF base≈9.07b ; Y1≈10.28b ; Y5≈14.00b
Fair Price DCF = 249.9 (EV 411.98b - Net Debt 24.52b = Equity 387.46b / Shares 1.55b; r=5.90% [WACC]; 5y FCF grow 15.61% → 2.90% )
EPS Correlation: 78.42 | EPS CAGR: 113.8% | SUE: N/A | # QB: 0
Revenue Correlation: 87.65 | Revenue CAGR: 6.46% | SUE: N/A | # QB: 0